AUM Biosciences presented on ‘Understanding the burgeoning Asian oncology market’ at the Biotech Investment Summit on 31 October – 2 November 2018

One Farrer Hotel & Spa, Singapore., 31 October – 2 November 2018

AUM Biosciences’ Co-Founder and CEO, Vishal Doshi gave a presentation on ‘Understanding the burgeoning Asian Oncology market’ at the Biotech Investment Summit on 31 October – 2 November at One Farrer Hotel & Spa in Singapore.

Over the recent years, Asia has seen an increasing prevalence of western cancers. Yet, treatments are not tailored to the Asian context and environment. In his presentation, Vishal provided an overview and understanding of the economics of treatment in Asia and the need for an Asia-centric development of cancer research and innovation. Additionally, global shifts in the treatment paradigm in Asian Oncology and the need to address the underserved Asia-specific cancers, was discussed.

Vishal was also invited to participate in a Panel Discussion at the Biopharma Development and Production 2018 Closing Plenary Session.

The Panel, titled, “Addressing Changing Financing Models, Advancement in Manufacturing, and Managing Cold/Non Chain Costs”, covered the following topics:

AUM Biosciences is enjoyed connecting with other industry experts and investors to explore opportunities on how we can make a positive impact to the Asian oncology space for the sustainable future.

More information about the event can be found here.

For any additional queries, please contact

About AUM Biosciences

AUM Biosciences (AUM) is an oncology-focused Asian biotechnology company committed to developing affordable cancer therapies. Dedicated to unlocking the value in innovation, AUM harnesses the power of precision medicine and digital health to support patients, physicians and partners. AUM focuses on earlystage development of innovative treatment of cancers prevalent in Asia with the potential to address global markets.

AUM develops potent and highly selective therapeutics in oncology, with an aim to change the drug development paradigm by implementing a holistic approach to developing drugs. AUM Biosciences is led by a highly-experienced management team with over 75 years of high-quality oncology drug development experience combined.

Headquartered in Singapore, AUM is strategically positioned to work, partner and collaborate with leading research institutes, clinicians and pharmaceutical companies globally. AUM is the recipient of Frost & Sullivan’s 2019 Asia-Pacific Biotech Entrepreneurial Company of the Year. For more information, please visit